U.S. Markets close in 4 hrs 31 mins
  • S&P 500

    3,626.97
    +49.38 (+1.38%)
     
  • Dow 30

    30,002.21
    +410.94 (+1.39%)
     
  • Nasdaq

    11,998.01
    +117.37 (+0.99%)
     
  • Russell 2000

    1,848.31
    +30.01 (+1.65%)
     
  • Crude Oil

    45.13
    +2.07 (+4.81%)
     
  • Gold

    1,802.90
    -34.90 (-1.90%)
     
  • Silver

    23.23
    -0.40 (-1.71%)
     
  • EUR/USD

    1.1888
    +0.0042 (+0.3566%)
     
  • 10-Yr Bond

    0.8770
    +0.0200 (+2.33%)
     
  • Vix

    22.06
    -0.60 (-2.65%)
     
  • GBP/USD

    1.3357
    +0.0035 (+0.2605%)
     
  • USD/JPY

    104.6300
    +0.1420 (+0.1359%)
     
  • BTC-USD

    19,251.18
    +799.21 (+4.33%)
     
  • CMC Crypto 200

    382.10
    +12.35 (+3.34%)
     
  • FTSE 100

    6,422.00
    +88.16 (+1.39%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

UROVANT ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of UROV and Encourages Investors to Contact the Firm

Bragar Eagel & Squire
·2 min read

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Urovant Sciences Ltd. (NASDAQ: UROV) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Sumitovant Biopharma Ltd.

Click here to learn more and participate in the action.

On November 12, 2020, Urovant announced that it had signed an agreement to be acquired by Sumitovant for approximately $584 million. Pursuant to the merger agreement, Urovant stockholders will receive $16.25 in cash for each share of Urovant common stock owned. The deal is scheduled to close in the first quarter of 2021.

Bragar Eagel & Squire is concerned that Urovant’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Urovant’s stockholders.

If you own shares of Urovant and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at investigations@bespc.com or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Melissa Fortunato, Esq.
Alexandra Raymond, Esq.
investigations@bespc.com
www.bespc.com